Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2021-11-04 Interim / Quarterly Rep…
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2021
2021-11-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 4, 2021, reporting the issuance of a press release announcing financial results for the three and nine months ended September 30, 2021. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is not "filed" for certain regulatory purposes. The document itself is a current report announcing the earnings release, not the earnings release document itself. The length is 4054 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Earnings Release (ER) announcement, specifically the Form 8-K current report announcing the earnings release.
2021-11-04 English
FORM 4 SUBMISSION
Director's Dealing
2021-11-02 English
FORM 4 SUBMISSION
Director's Dealing
2021-10-29 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 25, 2021, reporting the entry into a material definitive agreement—a Royalty Purchase Agreement between AnaptysBio and Sagard Healthcare Royalty Partners. The content focuses on the terms of this financing transaction involving monetization of future royalties and milestones. There are no financial statements or detailed financial performance data presented, only a description of the agreement and its terms. This type of filing is an update on company financing activities and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 7200 characters, which is substantive and not a mere announcement or certification, supporting this classification with high confidence.
2021-10-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. It announces a press release about a clinical program update and includes the press release as an exhibit. The document explicitly states that the information is furnished and not filed, and it does not contain financial statements or detailed financial data. The length is 3933 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of financial results, management discussion, or audit information. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-10-04 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.